| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anesthesiology | 6 | 2020 | 93 | 2.370 |
Why?
|
| Wearable Electronic Devices | 5 | 2022 | 101 | 1.670 |
Why?
|
| Anesthesia | 4 | 2017 | 211 | 1.600 |
Why?
|
| Postmenopause | 9 | 2019 | 123 | 1.010 |
Why?
|
| Research Design | 3 | 2023 | 687 | 0.900 |
Why?
|
| Students, Medical | 2 | 2018 | 356 | 0.850 |
Why?
|
| Anesthesiologists | 2 | 2020 | 36 | 0.820 |
Why?
|
| Faculty, Medical | 2 | 2018 | 262 | 0.810 |
Why?
|
| Weight Reduction Programs | 2 | 2021 | 57 | 0.800 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2022 | 22 | 0.780 |
Why?
|
| Dermatitis, Atopic | 1 | 2022 | 41 | 0.770 |
Why?
|
| Medicine | 1 | 2023 | 97 | 0.770 |
Why?
|
| History, 20th Century | 6 | 2020 | 384 | 0.750 |
Why?
|
| Schools, Medical | 2 | 2020 | 111 | 0.700 |
Why?
|
| Transplantation, Heterologous | 1 | 2020 | 254 | 0.670 |
Why?
|
| Physicians, Women | 1 | 2020 | 47 | 0.660 |
Why?
|
| History, 19th Century | 5 | 2020 | 116 | 0.650 |
Why?
|
| Receptor, ErbB-2 | 1 | 2022 | 515 | 0.640 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2022 | 263 | 0.630 |
Why?
|
| Cardiovascular Diseases | 6 | 2021 | 1886 | 0.630 |
Why?
|
| Succinylcholine | 1 | 2018 | 3 | 0.620 |
Why?
|
| Neuromuscular Depolarizing Agents | 1 | 2018 | 5 | 0.620 |
Why?
|
| Blood Transfusion | 1 | 2020 | 308 | 0.600 |
Why?
|
| Hippocratic Oath | 1 | 2017 | 5 | 0.590 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 140 | 0.580 |
Why?
|
| Pediatric Obesity | 2 | 2021 | 385 | 0.580 |
Why?
|
| Anesthesia, Dental | 1 | 2017 | 8 | 0.580 |
Why?
|
| Halothane | 1 | 2017 | 11 | 0.570 |
Why?
|
| Models, Statistical | 2 | 2020 | 472 | 0.570 |
Why?
|
| Patient Positioning | 1 | 2017 | 53 | 0.560 |
Why?
|
| Women's Health | 11 | 2017 | 132 | 0.560 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2014 | 305 | 0.550 |
Why?
|
| Anesthetics, Inhalation | 1 | 2017 | 45 | 0.550 |
Why?
|
| Melanoma | 5 | 2015 | 832 | 0.530 |
Why?
|
| Physicians | 1 | 2023 | 579 | 0.530 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1085 | 0.520 |
Why?
|
| Anesthesia, Conduction | 1 | 2016 | 20 | 0.520 |
Why?
|
| Aspirin | 3 | 2014 | 221 | 0.500 |
Why?
|
| Pediatricians | 1 | 2016 | 66 | 0.500 |
Why?
|
| Humans | 59 | 2024 | 124327 | 0.500 |
Why?
|
| Teaching | 2 | 2014 | 189 | 0.490 |
Why?
|
| Mobile Applications | 3 | 2021 | 92 | 0.460 |
Why?
|
| Alcohol Drinking | 2 | 2013 | 339 | 0.450 |
Why?
|
| Intensive Care Units | 1 | 2017 | 483 | 0.450 |
Why?
|
| Academic Medical Centers | 3 | 2023 | 302 | 0.450 |
Why?
|
| Skin Neoplasms | 7 | 2016 | 803 | 0.440 |
Why?
|
| Wine | 1 | 2013 | 15 | 0.440 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2013 | 24 | 0.440 |
Why?
|
| Education, Medical | 1 | 2017 | 287 | 0.430 |
Why?
|
| Pandemics | 1 | 2021 | 1102 | 0.420 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 671 | 0.420 |
Why?
|
| Radiation Oncology | 1 | 2013 | 23 | 0.420 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 2507 | 0.410 |
Why?
|
| Hip Fractures | 1 | 2013 | 67 | 0.400 |
Why?
|
| United States | 14 | 2020 | 10767 | 0.400 |
Why?
|
| Electric Stimulation Therapy | 1 | 2013 | 103 | 0.390 |
Why?
|
| Radiology | 1 | 2013 | 106 | 0.370 |
Why?
|
| Middle Aged | 33 | 2024 | 26442 | 0.370 |
Why?
|
| California | 3 | 2021 | 128 | 0.350 |
Why?
|
| Aged | 29 | 2021 | 19460 | 0.340 |
Why?
|
| Anti-HIV Agents | 1 | 2013 | 314 | 0.340 |
Why?
|
| Outpatients | 5 | 2023 | 254 | 0.340 |
Why?
|
| Female | 39 | 2024 | 66265 | 0.330 |
Why?
|
| Internship and Residency | 3 | 2020 | 1169 | 0.330 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2021 | 43 | 0.320 |
Why?
|
| Exercise | 5 | 2021 | 820 | 0.320 |
Why?
|
| Coronary Stenosis | 2 | 2021 | 73 | 0.320 |
Why?
|
| Longitudinal Studies | 6 | 2021 | 1333 | 0.310 |
Why?
|
| Atrial Fibrillation | 3 | 2021 | 637 | 0.310 |
Why?
|
| Incidence | 10 | 2022 | 3086 | 0.290 |
Why?
|
| Diet, Fat-Restricted | 2 | 2018 | 41 | 0.280 |
Why?
|
| Diet, Carbohydrate-Restricted | 2 | 2018 | 25 | 0.280 |
Why?
|
| HIV Infections | 1 | 2019 | 1888 | 0.280 |
Why?
|
| Prospective Studies | 13 | 2022 | 6084 | 0.280 |
Why?
|
| Diet, Reducing | 2 | 2018 | 90 | 0.270 |
Why?
|
| Cohort Studies | 12 | 2021 | 4730 | 0.260 |
Why?
|
| Telemedicine | 3 | 2021 | 434 | 0.260 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2016 | 71 | 0.250 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 1320 | 0.250 |
Why?
|
| Vitamin D | 3 | 2016 | 159 | 0.240 |
Why?
|
| Electrocardiography | 2 | 2021 | 968 | 0.240 |
Why?
|
| Menopause | 2 | 2015 | 71 | 0.230 |
Why?
|
| Male | 21 | 2024 | 60989 | 0.230 |
Why?
|
| Adult | 14 | 2024 | 29378 | 0.230 |
Why?
|
| Ritonavir | 1 | 2024 | 54 | 0.230 |
Why?
|
| Overweight | 4 | 2021 | 359 | 0.230 |
Why?
|
| Pyridines | 2 | 2022 | 229 | 0.210 |
Why?
|
| Causality | 1 | 2023 | 83 | 0.210 |
Why?
|
| Sports | 2 | 2021 | 59 | 0.200 |
Why?
|
| Antiviral Agents | 3 | 2024 | 746 | 0.200 |
Why?
|
| Risk Factors | 11 | 2019 | 10139 | 0.200 |
Why?
|
| Registries | 2 | 2019 | 1410 | 0.200 |
Why?
|
| Lung Neoplasms | 3 | 2016 | 1604 | 0.200 |
Why?
|
| Cells | 1 | 2021 | 27 | 0.190 |
Why?
|
| Body Mass Index | 2 | 2021 | 1550 | 0.190 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 1532 | 0.190 |
Why?
|
| Smoking | 3 | 2016 | 1037 | 0.190 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2021 | 2 | 0.190 |
Why?
|
| Renal Dialysis | 2 | 2018 | 849 | 0.180 |
Why?
|
| Piperazines | 1 | 2022 | 233 | 0.180 |
Why?
|
| Logistic Models | 6 | 2016 | 1804 | 0.180 |
Why?
|
| Community Participation | 1 | 2021 | 44 | 0.180 |
Why?
|
| Endpoint Determination | 1 | 2021 | 54 | 0.180 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2020 | 14 | 0.180 |
Why?
|
| History, 15th Century | 1 | 2020 | 14 | 0.180 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2020 | 18 | 0.180 |
Why?
|
| Leadership | 1 | 2023 | 229 | 0.180 |
Why?
|
| History, 17th Century | 1 | 2020 | 35 | 0.180 |
Why?
|
| History, Ancient | 1 | 2020 | 54 | 0.170 |
Why?
|
| Surveys and Questionnaires | 6 | 2022 | 3730 | 0.170 |
Why?
|
| Boston | 1 | 2020 | 110 | 0.170 |
Why?
|
| Life Expectancy | 1 | 2020 | 53 | 0.170 |
Why?
|
| Interleukins | 1 | 2021 | 120 | 0.170 |
Why?
|
| Sexism | 1 | 2020 | 38 | 0.170 |
Why?
|
| Patient Care Planning | 1 | 2021 | 122 | 0.170 |
Why?
|
| Social Class | 1 | 2021 | 191 | 0.170 |
Why?
|
| Weight Loss | 2 | 2021 | 482 | 0.170 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 117 | 0.170 |
Why?
|
| Polyethylene Glycols | 1 | 2021 | 223 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 236 | 0.160 |
Why?
|
| Tachycardia, Ventricular | 1 | 2021 | 197 | 0.160 |
Why?
|
| Receptors, Estrogen | 1 | 2022 | 793 | 0.160 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 68 | 0.160 |
Why?
|
| Social Dominance | 1 | 2018 | 9 | 0.160 |
Why?
|
| Machine Learning | 1 | 2021 | 242 | 0.160 |
Why?
|
| Heart Rate | 1 | 2021 | 588 | 0.160 |
Why?
|
| Prevalence | 2 | 2022 | 2428 | 0.150 |
Why?
|
| Veterans | 3 | 2019 | 1751 | 0.150 |
Why?
|
| Malignant Hyperthermia | 1 | 2018 | 19 | 0.150 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 231 | 0.150 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2018 | 61 | 0.150 |
Why?
|
| Smartphone | 1 | 2018 | 37 | 0.150 |
Why?
|
| Drug Industry | 1 | 2018 | 46 | 0.150 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2018 | 32 | 0.150 |
Why?
|
| Spasm | 1 | 2018 | 48 | 0.150 |
Why?
|
| Atrial Flutter | 1 | 2018 | 32 | 0.150 |
Why?
|
| Calcium, Dietary | 2 | 2015 | 37 | 0.150 |
Why?
|
| Weight Gain | 1 | 2021 | 404 | 0.150 |
Why?
|
| Drug Approval | 1 | 2018 | 42 | 0.150 |
Why?
|
| Algorithms | 3 | 2021 | 1612 | 0.150 |
Why?
|
| Vitamins | 2 | 2016 | 107 | 0.150 |
Why?
|
| Geriatric Assessment | 2 | 2018 | 173 | 0.150 |
Why?
|
| Cardiac Catheters | 1 | 2017 | 8 | 0.150 |
Why?
|
| Transducers, Pressure | 1 | 2017 | 12 | 0.150 |
Why?
|
| Coronary Artery Bypass | 1 | 2021 | 511 | 0.150 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2021 | 233 | 0.150 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 63 | 0.150 |
Why?
|
| Patient Education as Topic | 1 | 2021 | 443 | 0.150 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2020 | 668 | 0.150 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 150 | 0.150 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 872 | 0.140 |
Why?
|
| Poverty | 1 | 2021 | 418 | 0.140 |
Why?
|
| Curriculum | 2 | 2014 | 722 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2020 | 206 | 0.140 |
Why?
|
| Pneumonia | 1 | 2021 | 326 | 0.140 |
Why?
|
| Hyperkalemia | 1 | 2018 | 65 | 0.140 |
Why?
|
| Pressure Ulcer | 1 | 2017 | 77 | 0.140 |
Why?
|
| Obesity | 3 | 2018 | 2250 | 0.140 |
Why?
|
| Reproductive History | 1 | 2017 | 10 | 0.140 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 430 | 0.140 |
Why?
|
| Menstruation | 1 | 2017 | 28 | 0.140 |
Why?
|
| Genotype | 3 | 2018 | 2552 | 0.130 |
Why?
|
| Aggression | 1 | 2018 | 225 | 0.130 |
Why?
|
| Minnesota | 1 | 2016 | 132 | 0.130 |
Why?
|
| Computer Simulation | 1 | 2019 | 642 | 0.130 |
Why?
|
| Cause of Death | 1 | 2018 | 468 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2024 | 12279 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1240 | 0.130 |
Why?
|
| Ovarian Reserve | 1 | 2015 | 11 | 0.120 |
Why?
|
| Calcium Carbonate | 1 | 2015 | 10 | 0.120 |
Why?
|
| Double-Blind Method | 3 | 2024 | 1618 | 0.120 |
Why?
|
| Trinucleotide Repeats | 1 | 2015 | 110 | 0.120 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2015 | 37 | 0.120 |
Why?
|
| Insulin Resistance | 2 | 2018 | 643 | 0.120 |
Why?
|
| Gene-Environment Interaction | 1 | 2016 | 122 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2017 | 377 | 0.120 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2015 | 125 | 0.120 |
Why?
|
| Medicare | 1 | 2018 | 422 | 0.120 |
Why?
|
| Acute Disease | 1 | 2017 | 1101 | 0.120 |
Why?
|
| Nursing Homes | 1 | 2015 | 95 | 0.120 |
Why?
|
| Body Composition | 2 | 2016 | 524 | 0.120 |
Why?
|
| Medicine in Literature | 1 | 2014 | 3 | 0.110 |
Why?
|
| Museums | 1 | 2014 | 3 | 0.110 |
Why?
|
| Motion Pictures | 1 | 2014 | 8 | 0.110 |
Why?
|
| Multimedia | 1 | 2014 | 9 | 0.110 |
Why?
|
| Alcoholic Beverages | 1 | 2013 | 18 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 2 | 2018 | 874 | 0.110 |
Why?
|
| Coronary Vessels | 1 | 2017 | 537 | 0.110 |
Why?
|
| Cardiac Catheterization | 1 | 2017 | 632 | 0.110 |
Why?
|
| Textbooks as Topic | 1 | 2013 | 8 | 0.110 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2013 | 35 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1460 | 0.100 |
Why?
|
| Food Preferences | 1 | 2013 | 117 | 0.100 |
Why?
|
| Single-Blind Method | 3 | 2021 | 237 | 0.100 |
Why?
|
| Insulin | 1 | 2018 | 1207 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2013 | 93 | 0.100 |
Why?
|
| History of Medicine | 1 | 2012 | 4 | 0.100 |
Why?
|
| Europe | 1 | 2013 | 352 | 0.100 |
Why?
|
| Self Concept | 1 | 2013 | 161 | 0.100 |
Why?
|
| Virus Shedding | 2 | 2021 | 80 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 755 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2015 | 477 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 749 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 656 | 0.090 |
Why?
|
| Periodicals as Topic | 1 | 2013 | 196 | 0.090 |
Why?
|
| Data Collection | 1 | 2012 | 383 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 717 | 0.080 |
Why?
|
| Age Factors | 4 | 2018 | 2805 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1694 | 0.080 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1659 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 511 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 723 | 0.080 |
Why?
|
| Animals | 2 | 2020 | 34134 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2024 | 2896 | 0.070 |
Why?
|
| Stroke | 1 | 2015 | 974 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 1017 | 0.070 |
Why?
|
| Pediatrics | 1 | 2016 | 1160 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1241 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2018 | 16223 | 0.070 |
Why?
|
| Survival Rate | 2 | 2021 | 2020 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3133 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2018 | 1482 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 1099 | 0.060 |
Why?
|
| Young Adult | 4 | 2021 | 8978 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 484 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 6467 | 0.050 |
Why?
|
| Leukotriene B4 | 1 | 2023 | 7 | 0.050 |
Why?
|
| Fatigue | 2 | 2015 | 219 | 0.050 |
Why?
|
| Quality of Life | 1 | 2013 | 1949 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 2122 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1417 | 0.050 |
Why?
|
| Child | 2 | 2021 | 24516 | 0.050 |
Why?
|
| Sleep Wake Disorders | 2 | 2015 | 179 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2016 | 1246 | 0.050 |
Why?
|
| Emotions | 2 | 2015 | 365 | 0.050 |
Why?
|
| San Francisco | 1 | 2021 | 17 | 0.050 |
Why?
|
| Hematologic Tests | 1 | 2021 | 35 | 0.050 |
Why?
|
| Clinical Chemistry Tests | 1 | 2020 | 5 | 0.050 |
Why?
|
| Dietary Supplements | 2 | 2015 | 477 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2021 | 125 | 0.050 |
Why?
|
| Blood Sedimentation | 1 | 2020 | 28 | 0.050 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2020 | 45 | 0.050 |
Why?
|
| Operative Time | 1 | 2021 | 166 | 0.040 |
Why?
|
| Alkaline Phosphatase | 1 | 2020 | 98 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2020 | 108 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 247 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 273 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 342 | 0.040 |
Why?
|
| Calcium | 2 | 2015 | 1095 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2020 | 256 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 539 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2016 | 3268 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 274 | 0.040 |
Why?
|
| Confidentiality | 1 | 2019 | 99 | 0.040 |
Why?
|
| Creatinine | 1 | 2020 | 382 | 0.040 |
Why?
|
| Veterans Health | 1 | 2020 | 174 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 276 | 0.040 |
Why?
|
| Reoperation | 1 | 2021 | 830 | 0.040 |
Why?
|
| Conservative Treatment | 1 | 2018 | 33 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 461 | 0.040 |
Why?
|
| Time Factors | 2 | 2018 | 6262 | 0.040 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 127 | 0.030 |
Why?
|
| Health Status | 1 | 2019 | 374 | 0.030 |
Why?
|
| Menarche | 1 | 2017 | 34 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 171 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 818 | 0.030 |
Why?
|
| Telomere Homeostasis | 1 | 2016 | 42 | 0.030 |
Why?
|
| Keratinocytes | 1 | 2016 | 61 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 582 | 0.030 |
Why?
|
| Genes, Modifier | 1 | 2016 | 11 | 0.030 |
Why?
|
| Sunlight | 1 | 2016 | 23 | 0.030 |
Why?
|
| Lovastatin | 1 | 2016 | 27 | 0.030 |
Why?
|
| Mental Health | 1 | 2019 | 346 | 0.030 |
Why?
|
| RNA, Untranslated | 1 | 2016 | 112 | 0.030 |
Why?
|
| Length of Stay | 1 | 2021 | 1307 | 0.030 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2016 | 49 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 671 | 0.030 |
Why?
|
| Equipment Design | 1 | 2017 | 597 | 0.030 |
Why?
|
| Simvastatin | 1 | 2016 | 76 | 0.030 |
Why?
|
| Hot Flashes | 1 | 2015 | 6 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1149 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2017 | 427 | 0.030 |
Why?
|
| SEER Program | 1 | 2016 | 199 | 0.030 |
Why?
|
| Energy Intake | 1 | 2018 | 491 | 0.030 |
Why?
|
| Maternal Age | 1 | 2015 | 132 | 0.030 |
Why?
|
| Stents | 1 | 2021 | 884 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 284 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2016 | 159 | 0.030 |
Why?
|
| Receptors, Nicotinic | 1 | 2016 | 155 | 0.030 |
Why?
|
| Indoles | 1 | 2016 | 182 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2015 | 193 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 418 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 522 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2016 | 223 | 0.030 |
Why?
|
| Acetaminophen | 1 | 2014 | 92 | 0.030 |
Why?
|
| Family Therapy | 1 | 2013 | 34 | 0.030 |
Why?
|
| Skin | 1 | 2016 | 511 | 0.030 |
Why?
|
| Proteomics | 1 | 2016 | 489 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2013 | 178 | 0.030 |
Why?
|
| School Health Services | 1 | 2013 | 101 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 138 | 0.030 |
Why?
|
| Prognosis | 1 | 2021 | 4554 | 0.020 |
Why?
|
| Counseling | 1 | 2013 | 216 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2016 | 778 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 1614 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2871 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 606 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 2038 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2013 | 469 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 525 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 1113 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2016 | 722 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 3371 | 0.020 |
Why?
|
| Kidney | 1 | 2015 | 1345 | 0.020 |
Why?
|
| Genomics | 1 | 2016 | 1486 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2013 | 713 | 0.020 |
Why?
|
| Hospitalization | 1 | 2015 | 1753 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2614 | 0.020 |
Why?
|
| Diet | 1 | 2013 | 1132 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5106 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 3425 | 0.020 |
Why?
|
| Adolescent | 1 | 2015 | 19354 | 0.010 |
Why?
|